ArticleCureus2025
Delayed Diagnosis of Adult Granulosa Cell Tumor: Emphasizing the Importance of Comprehensive Ovarian Mass Evaluation and Standardized Laboratory Reporting.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulosa cell tumors (GCTs) are rare, non-epithelial ovarian tumors that secrete hormones such as estrogen and inhibin. They are classified as either adult GCTs (AGCTs) or juvenile GCTs (JGCTs). Timely detection is essential to control these malignant tumors and minimize the risk of further progression or spread. However, diagnostic challenges exist, as there are no standardized diagnostic criteria or comprehensive laboratory panels for GCT. In this case, a 36-year-old woman experienced a delayed diagnosis of AGCT, which was incidentally found during a routine ovarian cyst removal. A laboratory formatting error, which placed the quantitative value of inhibin B within the "in range" category, affected the patient's management course. This highlights the critical need for standardized diagnostic workups and laboratory result formats to improve the accuracy of diagnoses and prevent delays in treatment. Current diagnostic procedures often include imaging and serum markers such as inhibin B and anti-müllerian hormone (AMH). The lack of standardized diagnostic panels and the absence of clear guidance for non-gynecologic oncologists in diagnosing GCTs may contribute to misdiagnosis and delayed referrals. Recommendations include developing a standardized panel for GCTs, incorporating serum markers such as inhibin B, AMH, and follicle-stimulating hormone, and considering adding testosterone or estradiol levels based on clinical presentation. Additionally, molecular testing for a missense mutation in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.